I 025
Alternative Names: I-025; SPH-3261Latest Information Update: 28 Dec 2023
At a glance
- Originator Shanghai Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HER2 positive breast cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in HER2-positive-breast-cancer in China (PO, Capsule)